Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $21.25 USD
Change Today -0.43 / -1.98%
Volume 119.2K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

oncomed pharmaceuticals inc (OMED) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/23/15 - $29.83
52 Week Low
08/14/14 - $16.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

oncomed pharmaceuticals inc (OMED) Related Bloomberg News

View More Bloomberg News

oncomed pharmaceuticals inc (OMED) Related Businessweek News

No Related Businessweek News Found

oncomed pharmaceuticals inc (OMED) Details

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has completed preclinical trial that targets and inhibits DLL4 and vascular endothelial growth factor (VEGF); Tarextumab (Anti-Notch2/3, OMP-59R5), a human monoclonal antibody that targets the Notch2 and Notch3 receptors that is in Phase II clinical trials; Brontictuzumab (Anti-Notch1, OMP-52M51), a human monoclonal antibody, which completed single-agent Phase I trial for the treatment of solid tumor; and Vantictumab ((Anti-Fzd7, OMP-18R5) that completed a Phase I single-agent trial in tumor patients. Its products also include Ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based Frizzled8 receptor or Fzd8, which is in Phase I single agent trial; Wnt biologic #3, an additional bispecific biologic product candidate in preclinical studies; Wnt small molecule inhibitors, which is in preclinical testing; and RSPO-LGR, a CSC pathway that is in preclinical study of antibodies. OncoMed Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline LLC to develop anti-CSC antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for anti-CSC biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.

108 Employees
Last Reported Date: 03/12/15
Founded in 2004

oncomed pharmaceuticals inc (OMED) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $469.5K
Vice President and General Counsel
Total Annual Compensation: $383.8K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $364.7K
Compensation as of Fiscal Year 2014.

oncomed pharmaceuticals inc (OMED) Key Developments

OncoMed Pharmaceuticals, Inc. Appoints Rick Winningham to Board of Directors

OncoMed Pharmaceuticals, Inc. announced the appointment of Rick Winningham to the company's Board of Directors. Mr. Winningham is currently Chairman and Chief Executive Officer of Theravance Biopharma. Mr. Winningham serves as Chief Executive Officer and Chairman of the Board of Directors of Theravance Biopharma. From 2001-2014 he served as CEO of Theravance, Inc., during which time the company formed a transformational alliance with GlaxoSmithKline, completed a successful initial public offering, and advanced a number of products to commercialization before separating into two independent public companies, Theravance, Inc. and Theravance Biopharma.

OncoMed Pharmaceuticals, Inc. Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting

At the 2015 ASCO Annual Meeting, OncoMed Pharmaceuticals Inc. presented data from a Phase 1b study open-label trial of demcizumab plus carboplatin and pemetrexed (Alimta) in patients with first-line advanced stage non-small cell lung cancer (NSCLC). Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell, dysangiogenic and potential immune modulatory properties. Patients enrolled in the multi-center Phase 1b study either received six cycles of pemetrexed and carboplatin with demcizumab administered every three weeks on a continuous dosing schedule or four cycles of pemetrexed and carboplatin with truncated dosing of demcizumab followed by pemetrexed maintenance. Kaplan-Meier curves for the continuous dose cohort reveal prolonged progression-free survival and overall survival in a subset of demcizumab-treated patients. Of 23 patients in the continuous dosing cohort, ten (approximately 40%) survived more than two years. In these ten patients who survived more than 300 days, represented in the tail on the Kaplan-Meier survival curve, there was a cumulative 21.8 years of patient follow-up beyond those 300 days, and among these ten patients, only two patient deaths occurred as of the February 26, 2015 data cut off. Survival data from patients treated with the truncated demcizumab dose regimen is less mature, although the Kaplan-Meier curve shows a similar trajectory as of the February 2015 cut-off date. A retrospective analysis of patient tumor samples was conducted looking at a number of biomarkers related to demcizumab's mechanism of action, including tumor expression of the DLL4 protein, tumor expression of the programmed death receptor ligand-1 (PD-L1), and presence of immune cells within tumors, in order to identify potential predictive biomarkers for the apparent prolonged survival of certain patients treated with demcizumab. A total of 46 patients were enrolled in the Phase 1b study, with 40 evaluable for efficacy across both cohorts. One patient (3%) had a complete response, 19 (48%) had partial responses and 15 (38%) had stable disease as measured by RECIST criteria. The overall clinical benefit rate was 88%.

OncoMed Pharmaceuticals, Inc. - Special Call

To discuss clinical-stage company developing novel therapeutics that target cancer stem cell


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMED:US $21.25 USD -0.43

OMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMED.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.7x
Price/Book 9.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOMED PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at